2008 Gastrointestinal Oncology Conference Review |
2008 Gastrointestinal Oncology Conference Please click on abstract title to review abstract PDF file (opens in a new window). |
|
Session I: Esophageal Cancer | |
• |
Epidemiology and Biology of Esophageal Cancer Steven R. DeMeester |
• |
Principles of Modern Radiation Techniques for Esophageal and Gastroesophageal Junction Cancers |
Proffered Papers | |
• |
|
• |
Safety of Minimally Invasive Esophagectomy in Malignancy |
• |
|
Session 2: Pancreatic Cancer | |
• |
Are There Rational Novel Targets for Pancreatic Cancer Therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in Pancreatic Cancer James Abbruzzese |
• |
New Strategies for Success in Pancreatic Adenocarcinoma Eileen M. O’Reilly |
Proffered Papers | |
• |
Gene Expression Profiling Differentiates Drug-Sensitive and Drug-Resistant Pancreatic Cancer Cell Lines |
• |
Quality of Life in Patients with Advanced Pancreatic Cancer Receiving Gemcitabine, Capecitabine, and Bevacizumab: Results from a Prospective Multicenter Phase II Trial Anubba Bharthuar |
• |
Anterior Gradient 2 (AGR2) Is Expressed and Secreted During the Development of Pancreatic Cancer and Promotes Cancer Cell Survival Viji Ramachandran |
• |
First-Line Treatment of Metastatic Pancreatic Endocrine Carcinomas with Capecitabine and Temozolomide Jonathan Strosberg |
Session 3: Advanced Colorectal Cancer | |
• |
New Agents on the Horizon: Positioning Them for Advantage |
• |
Curable Metastatic Colorectal Cancer |
Proffered Papers | |
• |
Development of, and Initial Data from, a Clinical Pathway for the Treatment of Colon Cancer in the US Oncology Network |
• |
Systemic Chemotherapy with CapOx in Patients with Potentially Resectable Liver Metastases from Colorectal Cancer |
• |
Regulation of Sox9 and Wnt Signaling by Galectin-3 in Human Colon Cancer Cells |
• |
Eradication of Metastatic Colorectal Adenocarcinoma Resistant to Trastuzumab and Cetuximab After Treatment with Immunochemogene SEVINA-IV, a Stealth Nanoparticle Formulation Composed of Clamp PNA Against mRNA of sGCa1/b1, Anti-MUC1 Chimeric Mab, and Vinorelbine Tartrate John Giannios |
Session 4: Hepatobiliary Cancer | |
Proffered Papers | |
• |
ZBP-89 Enhances the Efficacy of Anti-Tumor Agents on Hepatocellular Carcinoma |
• |
Advanced Stage, Not Advanced Age, Influences the Survival of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma |
Session 5: Emerging Science | |
• |
The Future of Cancer Genomics: Lessons Learned from the Cancer Genome Atlas Project* |
• |
Statistical Aspects of Gene Signatures and Molecular Targets |
• |
Circulating Tumor Cells: A Promising Biomarker in GI Cancers |
Session 6: Adjuvant Colon Cancer | |
• |
Adjuvant Therapy of Colon Cancer: Lessons Learned and Challenges Ahead* |
Proffered Papers | |
• |
Prognostic Value of Prolactin in Colorectal Carcinoma |
• |
Novel Methodology to Evaluate Drugs for Gastrointestinal Malignancies |
• |
Insights on CRC Classification Based on Further Analyses of a Large Number of Cases |
• |
The Era of Individualization of Therapy: Focus on K-ras* |
Session 7: Gastric Cancer | |
• |
Localized Gastric/Gastroesophageal Cancer – Indications and Results of Chemoradiation |
• |
Chemoradiation Is Not Always Needed |
• |
Adjuvant Approaches to Gastric Cancer |
Proffered Papers | |
• |
Effect of Imatinib in Patients with Gastrointestinal Stromal Tumor |
• |
Adjuvant Chemotherapy in Completely Resected Gastric Cancer |
• |
Analysis of an Observational Registry of Gastrointestinal Stromal Tumor (GIST) Patients in the USA: reGISTry |
Session 8: Rectal Cancer | |
• |
Rectal Cancer - Redefining Clinical Stage Based on Outcomes Data |
• |
Chemoradiation: Are We at a Stand Still? |
• |
Lymph Node Counts and Survival Rates After Resection for Colon and Rectal Cancer |
Proffered Papers | |
• |
Increasing Incidence of Rectal Cancer in Patients Younger Than 40 Years of Age: An Analysis of the SEER Database |
• |
Submitting to an Oncology Journal: Tricks and Tips* |
Abstracts Selected for Poster Presentations | |
(note presenting authors appear in bold) | |
Esophageal Cancer | |
• |
Retrospective Study of Esophageal Cancer: A Small-Volume Single-Institution Experience for a 9-Year Period |
Pancreatic Cancer | |
• |
Updated Data Confirm Excellent Activity of Weekly “Metronomic Dosing” of Paclitaxel, Oxaliplatin, Leucovorin, and 5-Fluorouracil (POLF) in Metastatic Pancreatic Adenocarcinoma |
• |
Anti-Cancer Effect and Mechanism of Combination of Suberoylanilide Hydroxamic Acid (SAHA) and Bortezomib with Gemcitabine in Pancreatic Cancer Cell Lines Sang Hyub Lee, Jun Kyu Lee, Ki Young Yang, Jeong Kyun Seo, Joo Kyung Park, Jin-Hyeok Hwang, Ji Kon Ryu, Yong-Tae Kim, Yong Bum Yoon |
• |
Proton Radiotherapy for Pancreatic Cancer: A Dosimetric Comparison with Photons |
• |
Adjuvant Chemoradiotherapy for Ampullary Carcinomas |
Advanced Colorectal Cancer | |
• |
Safety of Chronic Low-Dose Capecitabine as Maintenance Therapy in GI Cancers |
Hepatobiliary Cancer | |
• |
Clinical Characteristics of Intrahepatic Biliary Cystic Tumors: Comparison with Intrahepatic Cystic Lesions |
Gastric Cancer | |
• |
Signet Ring Cell Metastasis with Unknown Primary |
• |
Treatment Outcomes of Oxaliplatin, 5-Fluorouracil, and Leucovorin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer: A Retrospective Analysis |
©2022 International Society of Gastrointestinal Oncology | info@isgio.org |